EU Alzheimer Approval Challenges: Anavex Withdr...

By João L. Carapinha

March 26, 2026

Anavex Life Sciences has withdrawn its marketing authorization application for blarcamesine in early Alzheimer’s disease following feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). EU Alzheimer Ap...
South Africa Health Reform: Revitalizing the Crisis-Stricken Sector
NICE Pembrolizumab Recommendation for Locally Advanced Head and Neck Cancer T...
PEPFAR TB Impact: Averting Millions of Cases and Deaths Among HIV Patients
Vitamin B6 Depletion Risk in Carbidopa/Levodopa Therapy and Seizure Implications
Advancing Collaborative TB Innovation to Tackle Drug Resistance
Citation Analysis of Real-World Evidence in Medicare Drug Price Negotiations
Serplulimab Lung Cancer Treatment: Evaluation of Clinical and Economic Impact...
Cost-Effectiveness of T1D Screening Effectiveness in Canadian Children
Novartis Acquires Mutant-Selective PI3Kα Inhibitor to Enhance Breast Cancer T...
Semaglutide India Partnership: Enhancing Access to Diabetes Treatment
Wegovy HD Approval: A Game Changer in Obesity Treatment and Weight Loss Efficacy
Milestone Approval of Invasive Brain-Computer Interface Revolutionizes Spinal...